BioLineRx is trading 5.4% down at $2.12 before the October 12, 2026 market open; no clear company-specific announcement explaining the decline surfaced in available search results.
- Shares closed at $2.22 on October 9.
- The latest company release found was an October 8 announcement of planned GLIX1 presentations at the November Society for Neuro-Oncology meeting; it does not clearly explain the move.
- Major indices are mixed and modestly changed in the supplied market context, offering no clear broad-market explanation.